Characterization of Shiga Toxin-Producing &lt;i&gt;Escherichia coli&lt;/i&gt; Isolated from Humans between 2011 and 2014

Güleşen, Revasiye; Levent, Belkıs; Demir, Tülin; Akgeyik, Mesut; Kuran, Sibel Bulgurcuoğlu

doi:10.7883/yoken.jjid.2015.346

Cited by 3 publications

(3 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…National Reference Laboratory at Ankara, Turkey, found that 62.5% of the non-O157 STEC isolates were resistant to at least one antibiotic (Gulesen, Levent, Demir, Akgeyik, & Kuran, 2016 The reason for this difference in prevalence of AR-STEC is not known but these studies suggest that there is a prevalence of resistance among STEC isolates from both animal and human sources. (Naseer, Lobersli, Hindrum, Bruvik, & Brandal, 2017).…”

Section: Analysis Of the Clinical (Human) Stec Isolates Collected By Thementioning

confidence: 96%

“…Analysis of the clinical (human) STEC isolates collected by the National Reference Laboratory at Ankara, Turkey, found that 62.5% of the non‐O157 STEC isolates were resistant to at least one antibiotic (Gulesen, Levent, Demir, Akgeyik, & Kuran, ). A study in the United Kingdom identified resistance to ampicillin, streptomycin, sulphonamide and tetracycline among the STEC isolates recovered from patients with diarrhoea (81/430; 18%; Day et al, ).…”

Section: Prevalence Of Ar‐stec In Animal Produce and Clinical Sourcesmentioning

confidence: 99%

See 1 more Smart Citation

Antibiotic‐resistant Shiga toxin‐producing Escherichia coli: An overview of prevalence and intervention strategies

Mir

Kudva

2018

Zoonoses and Public Health

View full text Add to dashboard Cite

Shiga toxin‐producing Escherichia coli (STEC) are foodborne pathogens that can cause severe diseases, including bloody diarrhoea and kidney failure, in humans, while remaining harmless to its primary reservoir hosts, cattle. Antibiotics such as azithromycin, fosfomycin and meropenem are being used and recommended in the treatment of early‐stage STEC (mainly E. coli O157:H7) infections, as these are reportedly effective in preventing Shiga toxin release and kidney failure while eliminating the pathogen. However, antibiotic resistance among STEC isolates could negatively impact these and other similar treatment options while contributing towards the spread of antibiotic resistance genes especially if encoded on mobile genetic elements like plasmids. Antibiotic resistance among STEC isolates recovered from animals and patients is being reported globally. A comprehensive understanding of the prevalence of antibiotic‐resistant STEC (AR‐STEC) and the mechanisms promoting this resistance among these bacteria could help direct therapies and develop strategies to effectively reduce/eliminate these pathogens. Here, we have reviewed literature from the past three decades to gain insights on this prevalence and its impact on human infections. In addition, we have reviewed various strategies proposed by researchers to control STEC that in turn would be applicable to AR‐STEC as well.

show abstract

Section: Analysis Of the Clinical (Human) Stec Isolates Collected By Thementioning

confidence: 96%

Section: Prevalence Of Ar‐stec In Animal Produce and Clinical Sourcesmentioning

confidence: 99%

Antibiotic‐resistant Shiga toxin‐producing Escherichia coli: An overview of prevalence and intervention strategies

Mir

Kudva

2018

Zoonoses and Public Health

View full text Add to dashboard Cite

show abstract

“…A similar report from the UK reported a prevalence of genotypic resistance as 27.3 % in non-O157 and 17.4 % in O157 strains [18,25]. A higher prevalence of AMR in non-O157 STEC than in O157 STEC has also been reported from various phenotypic studies [19,20,32]. Also, we observed a higher percentage of MDR among the non-O157 strains compared to O157 STEC (8.8 and 7 %), although this was not significant.…”

Section: Discussionmentioning

confidence: 99%

Prevalence of genotypic antimicrobial resistance in clinical Shiga toxin-producing Escherichia coli in Norway, 2018 to 2020

Ramstad

Brandal

Taxt

et al. 2021

Journal of Medical Microbiology

View full text Add to dashboard Cite

Introduction. Shiga toxin-producing Escherichia coli (STEC) can cause severe to fatal disease in humans. Antimicrobial treatment is sometimes necessary, but contraindicated due to undesirable clinical outcome. However, recent studies have shown promising outcomes following antimicrobial treatment. Before the establishment of a possible antimicrobial treatment strategy for STEC infections, the prevalence of antimicrobial resistance in STEC needs to be determined. Gap Statement. The resistance status of Norwegian clinical STEC is not known and should be assessed. Aim. We aim to characterize genotypic antimicrobial resistance determinants in clinical STEC in Norway, and determine the prevalence of genotypic resistance in order to inform possible antimicrobial treatment options for STEC infections. Methodology. We included all clinical STEC submitted to the Norwegian Reference Laboratory from March 2018 to April 2020. All samples were whole-genome sequenced and screened for genotypic antimicrobial resistance,virulence determinants and plasmid incompatibility groups. We performed phylogenetic clustering of STEC by core-genome multi-locus sequence typing, and statistical association analyses between isolate characteristics and genotypic resistance. Results. A total of 459 STEC were analysed. For 385 (83.9 %) STEC we did not identify any antimicrobial resistance determinants. Seventy-four STEC (16.1 %) harboured antimicrobial resistance determinants against one or more antimicrobial classes. The most frequent genotypic resistance was identified against aminoglycosides (10.5 %). Thirty-nine STEC (8.5 %) had a multi-drug resistance (MDR) genotype. Genotypic resistance was more prevalent in non-O157 than O157 STEC (P=0.02). A positive association was seen between genotypic resistance and the low-virulent STEC O117:H7 phylogenetic cluster (no. 14) (P<0.001). Genotypic resistance was not significantly associated to high-virulent STEC. STEC O146:H28 and isolates harbouring the plasmid replicon type IncQ1 were positively associated with MDR. Conclusion. The overall prevalence of genotypic resistance in clinical STEC in Norway is low (16.1 %). Genotypic resistance is more prevalent in non-O157 strains compared to O157 strains, and not significantly associated to high-virulent STEC. Resistance to antimicrobials suggested for treatment, especially azithromycin is low and may present an empiric treatment alternative for severe STEC infections.

show abstract

Prevalence and some virulence genes of Escherichia coli O157 isolated from chicken meats and giblets

Güran

Vural

Erkan

et al. 2017

Annals of Animal Science

View full text Add to dashboard Cite

Escherichia coli o157 related foodborne illnesses continue to be one of the most important global public health problems in the world. this study aims to determine E. coli o157 prevalence in 375 chicken meat parts and giblets. the samples were collected randomly from several supermarkets and butchers in Diyarbakir, a city in southeast Turkey. They were analyzed and confirmed using the immunomagnetic separation (ims), vitek ® 2 microbial identification system and polymerase chain reaction (Pcr) method. this study also aims to detect the presence of fliC h7 , eaea, stx 1 , stx 2 and hlya genes by using Pcr. the overall E. coli o157 prevalence in chicken meat parts and giblets was 1.3%. all of the E. coli o157 isolates carried rfbE o157 and eaea genes; but not any fliC h7 and hlya genes. the E. coli o157 isolates obtained from drumstick and breast meat carried either stx 1 or stx 2 genes, which were related to important virulence factors of the disease. key words: E. coli o157, chicken meat, stx 1 , stx 2 , eaea, hlya Verotoxin-producing E. coli (VTEC) or Shiga toxin-producing E. coli (STEC) can lead to sporadic cases and outbreaks that can cause several illnesses, such as hemolytic colitis (HC) and hemolytic uremic syndrome (HUS), following the onset of diarrhea. The strain of E. coli is also known as enterohemorrhagic E. coli (EHEC); and EHEC-related diseases are most frequently caused by the E. coli O157:H7 serotype. This bacterium can be transmitted to humans through contaminated food, water, direct contact with animals and human-to-human transmission, and can cause serious diseases (Chinen et al., 2009; Karmali et al., 2010; Baker et al., 2016). Shigatoxigenic E. coli serotype O157 has the highest prevalence in the world in recent years. For example, it has been reported that 6,658 of 13,524 STEC-sourced infections in Europe were caused by the O157 serotype of E. coli between and 2010 (Messens et al., 2015. In England and Wales, 335 outbreaks took place between 1983 and 2012, and 14,184 laboratory-confirmed STEC O157 cases were observed Unauthenticated Download Date | 5/8/18 5:35 AM

show abstract

Characterization of Shiga Toxin-Producing <i>Escherichia coli</i> Isolated from Humans between 2011 and 2014

Cited by 3 publications

References 28 publications

Antibiotic‐resistant Shiga toxin‐producing Escherichia coli: An overview of prevalence and intervention strategies

Antibiotic‐resistant Shiga toxin‐producing Escherichia coli: An overview of prevalence and intervention strategies

Prevalence of genotypic antimicrobial resistance in clinical Shiga toxin-producing Escherichia coli in Norway, 2018 to 2020

Prevalence and some virulence genes of Escherichia coli O157 isolated from chicken meats and giblets

Contact Info

Product

Resources

About